Emergent secures $704m contract for Ebola treatment Ebanga

01 Aug 2023
www.pharmaceutical-technology.com
Vaccine
Emergent secures $704m contract for Ebola treatment Ebanga
Preview
Source: Pharmaceutical Technology
Phalguni Deswal
@Phalguni_GD
Emergent secures $704m contract for Ebola treatment Ebanga
Preview
Source: Pharmaceutical Technology
The contract is divided into two option periods, one advanced development option worth $121m, and the second procurement option valued at $583m over a five-year period. Image Credit: Belen B Massieu / Shutterstock.
Emergent BioSolutions has won a ten-year contract worth up to $704m to develop Ebanga (ansuvimab-zykl), a treatment approved by the US Food and Drug Administration (FDA) for the Ebola virus disease (EVD).
The contract has been given by the Biomedical Advanced Research and Development Authority (BARDA), which is part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS).
Recommended Reports
Emergent secures $704m contract for Ebola treatment Ebanga
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Malaria [Strain 7G8] Vaccine in Malaria GlobalData
Emergent secures $704m contract for Ebola treatment Ebanga
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - AT-752 in Dengue Fever GlobalData
View allCompanies IntelligenceEmergent BioSolutions IncHH&S LtdEmergent Inc.The U.S. governmentDepartment of HealthView all
Following the news, Emergent’s share price increased by 14.68% premarket on 1 August, compared to the market close on the previous day. Emergent’s market cap is $392.99m.
Under the deal, Emergent will be responsible for the advanced development, manufacturing scale-up, and procurement of Ebanga, a monoclonal antibody.
Emergent has other prior relationships with the US Government.
In January 2023, the company was awarded a $379.6m contract by the US Department of Defense for the procurement of a reactive skin decontamination lotion kit, Supply RSDL, for the removal of the chemical warfare agent from the skin.
The ten-year contract is divided into two option periods, comprising one advanced development option valued at $121m, and the second procurement option valued at $583m over a five-year period.
The advanced development activities consist of the post-licence development of Ebanga, including technology transfer as part of scaling up manufacturing, submission of a supplemental biologics licence application to the FDA, and completion of stability studies.
In May 2023, Emergent sold its travel vaccine portfolio, which included vaccines for typhoid fever, cholera, and Chikungunya virus to Bavarian Nordic. Infectious diseases are a growing market, with GlobalData forecasting $150bn in global annual sales in 2029.
GlobalData is the parent company of Pharmaceutical Technology.
In the press release, Emergent senior VP Paul Williams said: “Emergent is proud to continue providing solutions to and partnering with the [US] government to strengthen the medical countermeasure infrastructure that enables the development, manufacture, and delivery of essential treatments for deadly diseases.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.